AC Immune (NASDAQ: ACIU) isn't a familiar name to many investors, but that might be changing. The Switzerland-based biotech saw its stock zoom nearly 15% skyward on Tuesday, following news of a favorably revised collaboration agreement with a pharmaceutical sector titan within our borders. AC Immune, a clinical-stage biotech that develops precision medicine targeting neurodegenerative disorders, i...
AC Immune (NASDAQ: ACIU) isn't a familiar name to many investors, but that might be changing. The Switzerland-based biotech saw its stock zoom nearly 15% skyward on Tuesday, following news of a favorably revised collaboration agreement with a pharmaceutical sector titan within our borders. AC Immune, a clinical-stage biotech that develops precision medicine targeting neurodegenerative disorders, is currently in a partnership with Eli Lilly . The two companies have a license and collaboration agreement centered on AC Immune's Morphomer platform, from which it aims to develop next-generation treatments for Alzheimer's disease and other neurodegenerative afflictions. Image source: Getty Images. Continue reading
Nvidia stock was down for much of Tuesday but ended the trading session up slightly amid concerns that the Iran war was set to escalate. The stock was down throughout the day after reports that the U.S. had attacked military targets on Kharg Island, from which much of Iran’s oil is exported. News that Alphabet’s Google had signed a long-term contract with Broadcom didn’t seem to have much impact o...
Nvidia stock was down for much of Tuesday but ended the trading session up slightly amid concerns that the Iran war was set to escalate. The stock was down throughout the day after reports that the U.S. had attacked military targets on Kharg Island, from which much of Iran’s oil is exported. News that Alphabet’s Google had signed a long-term contract with Broadcom didn’t seem to have much impact on shares.
skynesher/E+ via Getty Images Octave Specialty Group ( OSG ) and some of its subsidiaries amended their credit agreement, under which they will get an additional $40M term loan. The company will use the term loan to, among other things, pay OSG subsidiary Cirrata UK's obligation to honor the put rights exercised in March 2026 by certain minority shareholders of Octave Specialty Ltd., a private lim...
skynesher/E+ via Getty Images Octave Specialty Group ( OSG ) and some of its subsidiaries amended their credit agreement, under which they will get an additional $40M term loan. The company will use the term loan to, among other things, pay OSG subsidiary Cirrata UK's obligation to honor the put rights exercised in March 2026 by certain minority shareholders of Octave Specialty Ltd., a private limited company incorporated in England and Wales. After the amendment, the total amount of term loans is $139,375,000 as of April 1, 2026, Octave ( OSG ) said. The additional term loan has the same maturity date and interest rate as Octave's ( OSG ) existing term loan. In relation to the amendment, the company pledged its interests in the capital stock of Everspan Holdings LLC, a Delaware limited liability company. Ambac Financial Group rebranded as Octave Specialty Group ( OSG ) in November 2025. More on Octave Specialty Octave: Still Waiting On The Turnaround Octave Specialty Group, Inc. (OSG) Q4 2025 Earnings Call Transcript Octave Specialty Group, Inc. 2025 Q4 - Results - Earnings Call Presentation Seeking Alpha’s Quant Rating on Ambac Financial Group Historical earnings data for Ambac Financial Group
deberarr U.S. stocks closed mixed on Tuesday as the S&P 500 ( SP500 ) and the Nasdaq Composite ( COMP:IND ) advanced to end in the green after reports that Pakistan is mediating a two-week ceasefire deal between the U.S. and Iran. The benchmark S&P 500 ( SP500 ) ended +0.1%, while the Nasdaq Composite ( COMP:IND ) closed +0.1%, and the blue-chip Dow ( DJI ) finished -0.2%. Over in the bond market,...
deberarr U.S. stocks closed mixed on Tuesday as the S&P 500 ( SP500 ) and the Nasdaq Composite ( COMP:IND ) advanced to end in the green after reports that Pakistan is mediating a two-week ceasefire deal between the U.S. and Iran. The benchmark S&P 500 ( SP500 ) ended +0.1%, while the Nasdaq Composite ( COMP:IND ) closed +0.1%, and the blue-chip Dow ( DJI ) finished -0.2%. Over in the bond market, the benchmark 10-year Treasury yield ( US10Y ) was 4 basis points lower at 4.30%, while the 2-year Treasury yield ( US2Y ) dropped 5 basis points to 3.81%. Crude oil futures ( CL1:COM ) were slightly lower at $111, while Brent ( CO1:COM ) was at $105 per barrel. Now, here are three things to focus on: President Donald Trump gave the Iranian regime a deadline of 8 p.m. to accept U.S. conditions and open the Strait of Hormuz, threatening that the country could be “taken out in one night” if the deadline is not met. In another Truth Social post, Trump also threatened the destruction “of a whole civilization” if Tehran does not agree to U.S. terms. Investors will monitor how these geopolitical developments will affect Wednesday’s stock market. Investors will receive the Federal Reserve’s minutes from its last meeting, where interest rates were held unchanged at 3.50%-3.75%. The Fed is expected to emphasize its cautious "higher-for-longer" stance on rates, as Wall Street prices in little to no interest rate cuts this year. When it comes to second-quarter earnings, notable companies expected to report include Delta Air Lines ( DAL ), Constellation Brands ( STZ ), Applied Digital ( APLD ), PriceSmart ( PSMT ), NovaBridge Biosciences ( NBP ), and Resources Connection ( RGP ), among others. More on the markets Iran Could Be The Tipping Point For The Consumer-Led Economy About Those Orders For Durable Goods That Factories In The U.S. Received Stocks From Liberation Day To Iran War S&P 500, Nasdaq crawl out of red territory as Iran is reportedly reviewing two-week ceasefire deal Why ...
Sundry Photography/iStock Editorial via Getty Images On Wednesday, Nutanix ( NTNX ) BoD approved an additional ~$750M share buyback, taking total authorization (including the remaining $29M) to ~$779M, to support growth and innovation. No fixed timeline; the program can be altered or stopped anytime, with no guarantee of any fixed share repurchases . NTNX stock closed at $39.50 and remained flat i...
Sundry Photography/iStock Editorial via Getty Images On Wednesday, Nutanix ( NTNX ) BoD approved an additional ~$750M share buyback, taking total authorization (including the remaining $29M) to ~$779M, to support growth and innovation. No fixed timeline; the program can be altered or stopped anytime, with no guarantee of any fixed share repurchases . NTNX stock closed at $39.50 and remained flat in after-hours trading. More on Nutanix Nutanix, Inc. (NTNX) Presents at Morgan Stanley Technology, Media & Telecom Conference 2026 Transcript Nutanix: Demand Surge Is Now Running Into Supply Constraints Nutanix, Inc. 2026 Q2 - Results - Earnings Call Presentation Lowest Quant ranked large-cap stocks with positive EPS surprises Nutanix outlines $2.8B–$2.84B FY26 revenue target amid AMD partnership and supply chain delays
Nicolae Popescu/iStock via Getty Images It pays to have hard assets in a volatile market, especially when said assets generate a steady stream of income and are trading with a margin of safety. While big names in the healthcare space like Welltower ( WELL ) and Ventas ( VTR ) grab much of the attention, I see value in lesser-followed names that offer the best of both worlds: high yield/value and g...
Nicolae Popescu/iStock via Getty Images It pays to have hard assets in a volatile market, especially when said assets generate a steady stream of income and are trading with a margin of safety. While big names in the healthcare space like Welltower ( WELL ) and Ventas ( VTR ) grab much of the attention, I see value in lesser-followed names that offer the best of both worlds: high yield/value and growth potential. This brings me to Healthcare Realty Trust ( HR ), which I last covered in January, highlighting its robust fundamentals, attractive valuation, and strong growth outlook. HR has since delivered a 4% total return, far outpacing the 4% decline in the S&P 500 ( SPY ) over the same timeframe. At the current price of $17.29, HR remains attractive with a forward P/FFO of 10.8 and a +5% dividend yield, as shown below. HR Stock 1-Yr Trend (Seeking Alpha) In this article, I revisit HR, including recent business fundamentals , and discuss why it remains an attractive ‘Buy’ at present for income and value investors, so let’s dive in! Why HR? Healthcare Realty Trust is the only REIT to focus exclusively on owning, managing, and developing outpatient medical facilities across the U.S. It partners closely with leading health systems and physicians, providing mission-critical real estate that supports the ongoing shift from inpatient to outpatient care. After an operational reset including a new dividend rate and portfolio repositioning, management now frames the business as “Healthcare Realty 2.0.” Under this model, HR emphasizes disciplined capital allocation and a streamlined portfolio concentrated in high-growth markets. At present, HR has 562 properties covering 33 million square feet. Most of its annual base rent (90%) comes from the Top 50 MSAs in the U.S. As shown below, its top tenants are well-recognized health systems with mostly stellar credit ratings. Investor Presentation HR continued to demonstrate solid fundamentals during Q4 2025, with same-store NOI risin...
ROCKVILLE, Md., April 07, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology platform company committed to accelerating access to innovative medicines, today announced financial results for the full year ended December 31, 2025, and highlighted recent pipeline progress and business updates for its two lead investigational programs,...
ROCKVILLE, Md., April 07, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology platform company committed to accelerating access to innovative medicines, today announced financial results for the full year ended December 31, 2025, and highlighted recent pipeline progress and business updates for its two lead investigational programs, givastomig (Phase 2, directed to gastric cancer), and VIS-101 (Phase 2, targeting wet age-related macular degeneration, or wet AMD).
Xiao-I stock explodes higher on a significant patent victory against Apple. But AIXI shares remain a very high-risk proposition for disciplined investors in 2026.
Xiao-I stock explodes higher on a significant patent victory against Apple. But AIXI shares remain a very high-risk proposition for disciplined investors in 2026.